Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Coombes

Showing results (291-300 of 334) with videos related to

Pageof 34
Sort By:
Journal of the National Cancer Institute|February 15, 2014
Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agentsBing Z Carter, Po Yee Mak, Duncan H Mak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2014
VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapyErick Riquelme, Milind Suraokar, Carmen Behrens, et al.
Breast Cancer Research and Treatment|April 6, 2012
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept studyMarta Pestrin, Silvia Bessi, Fabio Puglisi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 3, 2010
Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrenceMeera Nanjundan, Lauren Averett Byers, Mark S Carey, et al.
Cancer Informatics|November 18, 2010
Blasted cell line namesJing Wang, Lauren A Byers, John S Yordy, et al.
Blood|April 9, 2013
Prognostic impact and targeting of CRM1 in acute myeloid leukemiaKensuke Kojima, Steven M Kornblau, Vivian Ruvolo, et al.
Cancer Science|April 7, 2018
eIF2β, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancerIchidai Tanaka, Mitsuo Sato, Toshio Kato, et al.
Cancer Science|February 7, 2017
Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancerTomohiko Kakumu, Mitsuo Sato, Daiki Goto, et al.
Blood|December 4, 2008
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimensKatherine I Lin, Constantine S Tam, Michael J Keating, et al.
Cancer Research|May 27, 2010
Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemiaTwee Tsao, Steven Kornblau, Stephen Safe, et al.
Pageof 34

Showing results (291-300 of 334) with videos related to

Sort By:
Pageof 34
Journal of the National Cancer Institute|February 15, 2014
Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agentsBing Z Carter, Po Yee Mak, Duncan H Mak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2014
VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapyErick Riquelme, Milind Suraokar, Carmen Behrens, et al.
Breast Cancer Research and Treatment|April 6, 2012
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept studyMarta Pestrin, Silvia Bessi, Fabio Puglisi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 3, 2010
Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrenceMeera Nanjundan, Lauren Averett Byers, Mark S Carey, et al.
Cancer Informatics|November 18, 2010
Blasted cell line namesJing Wang, Lauren A Byers, John S Yordy, et al.
Blood|April 9, 2013
Prognostic impact and targeting of CRM1 in acute myeloid leukemiaKensuke Kojima, Steven M Kornblau, Vivian Ruvolo, et al.
Cancer Science|April 7, 2018
eIF2β, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancerIchidai Tanaka, Mitsuo Sato, Toshio Kato, et al.
Cancer Science|February 7, 2017
Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancerTomohiko Kakumu, Mitsuo Sato, Daiki Goto, et al.
Blood|December 4, 2008
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimensKatherine I Lin, Constantine S Tam, Michael J Keating, et al.
Cancer Research|May 27, 2010
Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemiaTwee Tsao, Steven Kornblau, Stephen Safe, et al.
Pageof 34